Endocervical Adenocarcinomas and HPV Genotyping in an HIV Endemic Milieu - a Retrospective Study

Overview

Journal BMC Womens Health

Publisher Biomed Central

Date 2025 Jan 15

PMID 39815240

Authors

Lucilia Lovane

Gabriella Lillsunde Larsson

Satish Tulsidas

Carla Carrilho

Soren Andersson

Christina Karlsson

Affiliations

Soon will be listed here.

Abstract

Background: Cervical cancer is the most prevalent cancer in Mozambique, with endocervical adenocarcinoma accounting for approximately 5.5% of cases. Knowledge regarding the most prevalent HPV genotypes in endocervical adenocarcinoma is limited, within this setting. This study aimed to investigate human papillomavirus (HPV) prevalence and genotypes within a cohort of endocervical adenocarcinoma patients in the context of Mozambique's recently introduced vaccination programme, considering the country's HIV-endemic setting.

Methods: Forty consecutive cases of endocervical adenocarcinoma diagnosed at Maputo Central Hospital between 2017 and 2018, with limited clinical data available, were included. Human immunodeficiency virus (HIV) status was determined through serological data or in situ hybridisation on histopathological slides. HPV detection was performed using a multi-methodological approach, including Anyplex II, in-house polymerase chain reaction (PCR), and chromogenic and fluorescent in situ hybridisation techniques.

Results: All 40 cases exhibited HPV-dependent morphology. Fourteen of the 40 patients were HIV-positive. No significant differences were observed between the two groups regarding age, stage, or histopathological type. hrHPV16, 18, or 45 were detected in all cases. Notably, multiple hrHPV infections were identified exclusively in HIV-negative cases (10/26, p = 0.0075), with hrHPV18/45 co-infection being the most common (n = 8).

Conclusions: These findings suggest that the newly implemented quadrivalent vaccination programme has the potential to prevent morbidity and mortality from endocervical adenocarcinoma, irrespective of HIV infection status, in Mozambique's HIV-endemic environment.

References

Williams J, Kostiuk M, Biron V . Molecular Detection Methods in HPV-Related Cancers. Front Oncol. 2022; 12:864820. PMC: 9092940. DOI: 10.3389/fonc.2022.864820. View

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

Boothe M, Sathane I, Sema Baltazar C, Chicuecue N, Horth R, Fazito E . Low engagement in HIV services and progress through the treatment cascade among key populations living with HIV in Mozambique: alarming gaps in knowledge of status. BMC Public Health. 2021; 21(1):146. PMC: 7811257. DOI: 10.1186/s12889-020-10039-2. View

Bray F, Carstensen B, Moller H, Zappa M, Primic Zakelj M, Lawrence G . Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005; 14(9):2191-9. DOI: 10.1158/1055-9965.EPI-05-0231. View

Denny L, Anorlu R . Cervical cancer in Africa. Cancer Epidemiol Biomarkers Prev. 2012; 21(9):1434-8. DOI: 10.1158/1055-9965.EPI-12-0334. View

da Mata S, Ferreira J, Nicolas I, Esteves S, Esteves G, Lerias S . P16 and HPV Genotype Significance in HPV-Associated Cervical Cancer-A Large Cohort of Two Tertiary Referral Centers. Int J Mol Sci. 2021; 22(5). PMC: 7956391. DOI: 10.3390/ijms22052294. View

Mohosho M . HIV prevalence in patients with cervical carcinoma: A cohort study at a secondary hospital in South Africa. Medicine (Baltimore). 2021; 100(35):e27030. PMC: 8415995. DOI: 10.1097/MD.0000000000027030. View

Larsson G, Carlsson J, Karlsson M, Helenius G . Evaluation of HPV Genotyping Assays for Archival Clinical Samples. J Mol Diagn. 2015; 17(3):293-301. DOI: 10.1016/j.jmoldx.2014.12.004. View

Maueia C, Murahwa A, Manjate A, Andersson S, Sacarlal J, Kenga D . Identification of the Human Papillomavirus Genotypes, According to the Human Immunodeficiency Virus Status in a Cohort of Women from Maputo, Mozambique. Viruses. 2022; 14(1). PMC: 8780750. DOI: 10.3390/v14010024. View

10.

Pimenta J, Galindo C, Jenkins D, Taylor S . Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer. 2013; 13:553. PMC: 3871005. DOI: 10.1186/1471-2407-13-553. View

11.

Rasmussen S, Lewis Jr J, Mirabello L, Bass S, Yeager M, Corsten M . A Case of HPV-Associated Oropharyngeal Squamous Cell Carcinoma with Block-Like, Partial Loss of p16 Expression. Head Neck Pathol. 2022; 16(4):1251-1256. PMC: 9729667. DOI: 10.1007/s12105-022-01463-4. View

12.

Kaliff M, Karlsson M, Sorbe B, Mordhorst L, Helenius G, Lillsunde-Larsson G . HPV-negative Tumors in a Swedish Cohort of Cervical Cancer. Int J Gynecol Pathol. 2019; 39(3):279-288. PMC: 7147426. DOI: 10.1097/PGP.0000000000000612. View

13.

Stolnicu S, Park K, Kiyokawa T, Oliva E, McCluggage W, Soslow R . Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2021; 40(Suppl 1):S75-S91. PMC: 7888380. DOI: 10.1097/PGP.0000000000000751. View

14.

Shing J, Hu S, Herrero R, Hildesheim A, Porras C, Sampson J . Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial. Lancet Oncol. 2022; 23(7):940-949. PMC: 9255557. DOI: 10.1016/S1470-2045(22)00291-1. View

15.

Jenkins D, Molijn A, Kazem S, Pirog E, Alemany L, de Sanjose S . Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study. Int J Cancer. 2020; 147(9):2526-2536. DOI: 10.1002/ijc.33124. View

16.

Stolnicu S, Hoang L, Soslow R . Recent advances in invasive adenocarcinoma of the cervix. Virchows Arch. 2019; 475(5):537-549. PMC: 6864265. DOI: 10.1007/s00428-019-02601-0. View

17.

Luo R, Chen S, Li M, Li Y, Yang X, Liu L . HPV E6/E7 mRNA in situ hybridization in endocervical adenocarcinoma: implications for prognosis and diagnosis. Cancer Cell Int. 2021; 21(1):643. PMC: 8641184. DOI: 10.1186/s12935-021-02349-1. View

18.

Bishop J, Ma X, Wang H, Luo Y, Illei P, Begum S . Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol. 2012; 36(12):1874-82. PMC: 3500437. DOI: 10.1097/PAS.0b013e318265fb2b. View

19.

Stern P . Is immunotherapy a potential game changer in managing human papillomavirus (HPV) infection and intraepithelial neoplasia?. Tumour Virus Res. 2023; 16:200263. PMC: 10774942. DOI: 10.1016/j.tvr.2023.200263. View

20.

Craig S, Anderson L, Moran M, Graham L, Currie K, Rooney K . Comparison of Molecular Assays for HPV Testing in Oropharyngeal Squamous Cell Carcinomas: A Population-Based Study in Northern Ireland. Cancer Epidemiol Biomarkers Prev. 2019; 29(1):31-38. PMC: 9158515. DOI: 10.1158/1055-9965.EPI-19-0538. View